PharmAla Biotech licenses ALA-002 U.S. rights to Jupiter Neurosciences
PharmAla Biotech Holdings has signed a term sheet granting Jupiter Neurosciences exclusive, perpetual rights to commercialise and develop ALA-002 in the United States, in a deal the Toronto-based company values at more than US$100 million across upfront payments, development milestones, and single-digit royalties on net sales.
Under the terms of the proposed transaction, PharmAla would receive US$3.33 million at closing — split between US$1.5 million in cash and US$1.83 million in Jupiter common stock, subject to a 10-day lock-up. Jupiter has placed US$600,000 into escrow on signing, which counts towards that upfront cash consideration; if the parties fail to execute a definitive agreement within 90 days, PharmAla retains the escrowed sum as a reverse termination fee. PharmAla retains all rights to ALA-002 outside the United States, including through its Cortexa joint venture in Australia.
The asset
ALA-002 is a patented, non-racemic MDMA formulation that has received Novel Chemical Entity designation from the FDA — a distinction that, if carried through to approval, would confer five years of market exclusivity in the United States. The company says it has engineered the molecule to offer improved cardiovascular safety and reduced abuse liability relative to racemic MDMA, while preserving the pro-social and therapeutic properties considered central to MDMA-assisted psychotherapy. PharmAla's clinical-grade MDMA is currently supplied into U.S. government-sponsored trials, including studies funded by the Department of Veterans Affairs and the Defense Health Agency.
Nicholas Kadysh, founding chief executive of PharmAla, said the transaction represents "a meaningful validation of the years of scientific, regulatory and manufacturing work PharmAla has invested in building ALA-002 into a credible, next-generation MDMA candidate," adding that retaining ex-U.S. rights allows the company to continue expanding through Cortexa and its broader MDXX-class pipeline globally.
Market context
The MDMA-assisted therapy space has faced a significant setback. The FDA declined to approve Lykos Therapeutics' MDMA-assisted therapy for post-traumatic stress disorder in August 2024, citing concerns about trial design and the difficulty of blinding in psychedelic studies. That decision reset commercial timelines across the sector and increased regulatory scrutiny on the entire MDXX class. ALA-002's NCE status could give it a cleaner path to a fresh NDA submission than a reformulated version of an existing molecule, but Jupiter will still need to generate its own Phase 2 and Phase 3 data — a substantial capital commitment for a NASDAQ-listed company whose market capitalisation sits well below the headline deal value.
The broader psychedelic therapeutics sector remains contested. Compass Pathways is advancing psilocybin in treatment-resistant depression, and a number of university-spinout and venture-backed companies are pursuing MDMA analogues and entactogens with differentiated safety or pharmacokinetic profiles. Regulators on both sides of the Atlantic have signalled that they require robust, blinded outcome measures and independent data safety monitoring before any psychedelic-class molecule moves to priority review.
For PharmAla, the structure is designed to be non-dilutive: the upfront equity consideration comes in the form of Jupiter shares rather than a PharmAla share issuance, and milestone payments are contingent rather than drawn from cash reserves. Investors will focus on whether the definitive agreement closes within the 90-day window and, if it does, how Jupiter intends to fund the clinical programme through to a potential NDA filing.